We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » In Stunning Turnaround, Embattled Tenapanor Gets FDA Approval Following CRL
In Stunning Turnaround, Embattled Tenapanor Gets FDA Approval Following CRL
It’s rare, but it turns out a company seeking approval for a new indication can find success in the wake of an FDA Complete Response Letter (CRL) as is the case for Ardelyx’s Xphozah (tenapanor).